FIG. 1A




FIG. 1B Engineered Regulators




Figure 2




Figure 3



207
205
201
100
200
300
305
515
516
517
604
700
520
400
101
102
103

Figure 4



207
205
200
201
100
300
305
501
502
503
504
515
516
517
520
700
604
400
303
300
618
630
619
620
102
101
103

Figure 5



207
205
200
201
100
300
305
700
520
515
516
517
604
400
300
303
618
630
619
620
102
101
103

Figure 6



207
205
200
201
100
300
305
515
520
516
700
517
400
604
303
300
607
102
101
103

Figure 7



207
205
200
201
100
300
305
515
516
517
520
700
604
400
300
303
619
630
620
102
101
103

Figure 8




Figure 9



208
200
202
203
100
300
305
206
700
515
520
516
517
604
400
300
303
618
630
619
620
101
102
103

Figure 10



208
200
202
203
100
300
305
206
700
515
516
517
520
501
502
503
504
515
516
517
604
604
303
400
300
618
630
619
620
101
102
103
700

Figure 11A



40
CRIg
IgV
IgC2
C3b binding
Transmembrane /cytoplasmic domain
20
FH
50
CFHR1
60
CFHR5
70
CR2
Transmembrane/ cytoplasmic domain
81
CRIg-CR1-FH
82
CFHR1-CR1-FH
83
CFHR5-CR1-FH
84
CR2-CR1-FH

Figure 11B



100
400
700
300
300
520
630
800
802
305
515
516
517
604
304
618
619
620
IgV
IgC2
4
18
19
20
101

Figure 11C



100
400
700
300
520
630
200
210
515
516
517
604
304
619
620
1
2
4
19
20
101

Figure 11D




100
400
700
300
520
630
200
211
515
516
517
604
304
619
620
1
2
4
19
20
101

Figure 11E


100
400
700
300
300
800
520
630
801
305
515
516
517
604
304
619
620
1
2
3
4
4
19
20
101




Figure 12A




Figure 12B




Figure 13A




Figure 13B

Figure 14A





Figure 14B






Figure 14C




Figure 14D




Figure 15A

Figure 15B

Figure 15C

Figure 16



120
100
80
60
40
20
0
% Lysis
-3
-2
-1
0
1
2
3
Inhibitors [nM]
FH
KC001
KC032
KC033
KC035

Figure 17A





Figure 17B






Figure 17C





Figure 17D

Figure 18



Sample	IC50 [pM]	Valency
KC032	648.3	1
KC033	406.7	1
KC035	501.9	1
anti-VEGF Ab	256.4	2

Figure 19



207
205
100
200
201
300
305
515
516
517
518
303
908
909
520
300
920
400
101
102
103

Figure 20




Figure 21




Figure 22




Figure 23



C3b + sCR1
C3b + sCR1
C3b + FI + sCR1 + 25 nM
C3b + FI + sCR1 + 12.5 nM
C3b + KC041
C3b + KC041
C3b + FI + KC041 _ 25 nM
C3b + FI + KC041 + 12.5 nM
kDa
250
148
98
64
50
36
sCR1
α
KC041
β
α¹ (68kDa)
43 kDa
40 kDa
C3dg

Figure 24A




Figure 24B




Figure 25A




Figure 25B




Figure 26



FB+FD (Convertase)
KC041
FH
KC046
Steps
1
2
3
4
RU
100
80
60
40
20
0
-20
0
100
200
300
400
500
600
Time (Sec)

Figure 27




Figure 28




Figure 29




Figure 30



kDa
250
148
98
64
50
36
22
16
C3B+FI
C3b + FI + KC049
C3b + FI + KC050
α
β
α1 (68kDa)
43 kDa
40 kDa
C3dg
1, 90 min
1, 5, 10, 30, 60, 90 min
1, 5, 10, 30, 60, 90 min

Figure 31



kDa
250
148
98
64
50
36
22
16
6
C4b + FI, 1 min
C4b + FI, 90 min
C4b + FI + KC049, 60 min
C4b + FI + KC049, 90 min
C4b + FI + KC050, 60 min
C4b + FI + KC050, 90 min
α (84kDa)
β
C4d, 45kDa
γ, 33 kDa
25 kDa

Figure 32




A
Steps
1
2
3
4
Response (RU)
Time (Sec)
FB+FD (Convertase)
KC050
KC046
KC052
B
Steps
1
2
34
5
Response (RU)
Time (s)
FB+FD+FP
KC050
KC046
KC052

Figure 33


2.0
1.5
1.0
0.5
0.0
Abs
0.001
0.01
0.1
1
10
100
1000
Inhibitors [nM]
SEQ ID NO.124 - 0.58 nM
SEQ ID NO.125 - 0.22 nM
KC050 - 0.34 nM
KC052 - 0.30 nM